Blueprint Medicines Corp (BPMC)
104.92
-1.72
(-1.61%)
USD |
NASDAQ |
May 17, 16:00
104.92
0.00 (0.00%)
After-Hours: 18:52
Blueprint Medicines Revenue (Annual): 249.38M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 249.38M |
| December 31, 2022 | 204.04M |
| December 31, 2021 | 180.08M |
| December 31, 2020 | 793.74M |
| December 31, 2019 | 66.51M |
| Date | Value |
|---|---|
| December 31, 2018 | 44.52M |
| December 31, 2017 | 21.43M |
| December 31, 2016 | 27.77M |
| December 31, 2015 | 11.40M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
66.51M
Minimum
2019
793.74M
Maximum
2020
298.75M
Average
204.04M
Median
2022
Revenue (Annual) Benchmarks
| Ligand Pharmaceuticals Inc | 131.31M |
| Apellis Pharmaceuticals Inc | 396.59M |
| Alnylam Pharmaceuticals Inc | 1.828B |
| Biomarin Pharmaceutical Inc | 2.419B |
| Corcept Therapeutics Inc | 482.38M |